Home Alzheimer’s Disease Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive...

Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive Ovarian Cancer

A study designed to evaluate the addition of cediranib to olaparib (Lynparza) failed to meet its primary end point of improved progression-free survival (PFS), compared with chemotherapy, according to results presented at the 2020 ASCO Virtual Scientific Program.

However, study data suggested the combination showed comparable activity to standard of care platinum-based chemotherapy treatment for recurrent platinum-sensitive ovarian cancer. More, both olaparib alone and the cediranib/olaparib combination demonstrated substantial activity for patients with a germline BRCA (gBRCA) mutation.

“Three clinical studies have suggested the potential for synergy between anti-angiogenics and PARP inhibitors,” lead study author Joyce F. Liu, MD, MPH, of the Dana-Farber Cancer Institute, explained in the study’s presentation. “In pre-clinical studies in ovarian cancer cell lines, synergy…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments